Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of GLP-1 agonist liraglutide in antipsychotic-associated type 2 diabetes mellitus
2013-005395-18Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by University Medical Center Utrecht. Primary endpoint: Change in HbA1c from baseline to end of trial. Started Sep 2014; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-005395-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005395-18.